Lisa Maier
Concepts (601)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Berylliosis | 73 | 2021 | 193 | 14.510 |
Why?
| Beryllium | 59 | 2022 | 166 | 10.550 |
Why?
| Sarcoidosis | 31 | 2022 | 118 | 8.500 |
Why?
| Occupational Exposure | 36 | 2022 | 312 | 6.450 |
Why?
| Sarcoidosis, Pulmonary | 20 | 2021 | 57 | 5.850 |
Why?
| Occupational Diseases | 7 | 2022 | 146 | 2.740 |
Why?
| HLA-DP beta-Chains | 13 | 2021 | 81 | 2.420 |
Why?
| Chronic Disease | 48 | 2021 | 1650 | 1.960 |
Why?
| Lung Diseases | 8 | 2022 | 728 | 1.820 |
Why?
| Polymorphism, Genetic | 13 | 2021 | 661 | 1.600 |
Why?
| Adrenal Cortex Hormones | 5 | 2020 | 521 | 1.460 |
Why?
| Bronchoalveolar Lavage Fluid | 24 | 2021 | 632 | 1.450 |
Why?
| HLA-DP Antigens | 9 | 2011 | 33 | 1.390 |
Why?
| Lymphocytes | 13 | 2020 | 387 | 1.310 |
Why?
| CD4-Positive T-Lymphocytes | 19 | 2021 | 991 | 1.280 |
Why?
| Lung | 28 | 2022 | 3580 | 1.150 |
Why?
| Humans | 144 | 2022 | 115146 | 1.070 |
Why?
| Leukocytes, Mononuclear | 7 | 2021 | 498 | 1.060 |
Why?
| Tumor Necrosis Factor-alpha | 14 | 2021 | 1241 | 1.020 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 323 | 1.010 |
Why?
| Middle Aged | 72 | 2021 | 28958 | 1.000 |
Why?
| Genetic Predisposition to Disease | 14 | 2021 | 2197 | 0.990 |
Why?
| Case-Control Studies | 22 | 2021 | 3261 | 0.980 |
Why?
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 78 | 0.970 |
Why?
| Nicotine | 2 | 2021 | 267 | 0.960 |
Why?
| Lipopolysaccharide Receptors | 3 | 2015 | 94 | 0.950 |
Why?
| Gene Expression Regulation | 6 | 2021 | 2568 | 0.950 |
Why?
| Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 1244 | 0.900 |
Why?
| Environmental Exposure | 5 | 2021 | 394 | 0.880 |
Why?
| Lymphocyte Activation | 18 | 2014 | 1101 | 0.840 |
Why?
| Granuloma | 6 | 2021 | 85 | 0.800 |
Why?
| Aged | 45 | 2021 | 20309 | 0.800 |
Why?
| Alleles | 10 | 2018 | 772 | 0.790 |
Why?
| HLA Antigens | 3 | 2015 | 213 | 0.790 |
Why?
| Hypersensitivity | 6 | 2014 | 278 | 0.790 |
Why?
| Male | 79 | 2022 | 60969 | 0.790 |
Why?
| Mesalamine | 2 | 2017 | 8 | 0.780 |
Why?
| Drug Interactions | 1 | 2021 | 401 | 0.760 |
Why?
| Biomedical Research | 4 | 2022 | 588 | 0.750 |
Why?
| Female | 76 | 2022 | 63296 | 0.740 |
Why?
| Receptors, IgG | 2 | 2018 | 75 | 0.730 |
Why?
| Respiratory Hypersensitivity | 5 | 2012 | 76 | 0.720 |
Why?
| Biomarkers | 11 | 2022 | 3508 | 0.710 |
Why?
| Immunity, Cellular | 2 | 2017 | 303 | 0.680 |
Why?
| Disease Progression | 8 | 2020 | 2494 | 0.680 |
Why?
| Dyspnea | 2 | 2021 | 187 | 0.670 |
Why?
| Cough | 1 | 2018 | 93 | 0.660 |
Why?
| Cytokines | 8 | 2019 | 1964 | 0.650 |
Why?
| Adult | 55 | 2021 | 32202 | 0.640 |
Why?
| Microbiota | 3 | 2021 | 508 | 0.610 |
Why?
| Gene Expression Profiling | 3 | 2021 | 1582 | 0.610 |
Why?
| Phenotype | 10 | 2022 | 2861 | 0.600 |
Why?
| DNA Methylation | 2 | 2021 | 427 | 0.590 |
Why?
| Cell Proliferation | 13 | 2018 | 2373 | 0.590 |
Why?
| Proteins | 3 | 2020 | 954 | 0.580 |
Why?
| Macrophages, Alveolar | 4 | 2020 | 360 | 0.570 |
Why?
| Asthma | 3 | 2020 | 2038 | 0.570 |
Why?
| Genotype | 13 | 2021 | 1854 | 0.560 |
Why?
| Mycophenolic Acid | 1 | 2014 | 81 | 0.530 |
Why?
| Immunization | 4 | 2008 | 411 | 0.530 |
Why?
| Particle Size | 4 | 2014 | 386 | 0.510 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 326 | 0.500 |
Why?
| Models, Immunological | 3 | 2013 | 100 | 0.490 |
Why?
| Cardiomyopathies | 5 | 2020 | 310 | 0.470 |
Why?
| Odds Ratio | 6 | 2020 | 1063 | 0.460 |
Why?
| Air Pollutants, Occupational | 2 | 2010 | 38 | 0.460 |
Why?
| Glutamic Acid | 4 | 2007 | 213 | 0.440 |
Why?
| Periodicals as Topic | 1 | 2015 | 234 | 0.440 |
Why?
| Dendritic Cells | 2 | 2014 | 490 | 0.430 |
Why?
| Allergens | 4 | 2012 | 498 | 0.430 |
Why?
| Risk Factors | 14 | 2020 | 9105 | 0.420 |
Why?
| Lung Diseases, Interstitial | 2 | 2020 | 390 | 0.420 |
Why?
| Immunosuppressive Agents | 2 | 2014 | 679 | 0.420 |
Why?
| Medical Laboratory Personnel | 1 | 2010 | 12 | 0.410 |
Why?
| Vital Capacity | 4 | 2019 | 252 | 0.400 |
Why?
| Quality of Life | 7 | 2022 | 2250 | 0.400 |
Why?
| Receptors, CCR5 | 1 | 2010 | 51 | 0.390 |
Why?
| Antibodies, Monoclonal | 5 | 2012 | 1300 | 0.390 |
Why?
| Forced Expiratory Volume | 4 | 2018 | 555 | 0.390 |
Why?
| Endotoxins | 2 | 2010 | 265 | 0.390 |
Why?
| Th1 Cells | 3 | 2013 | 140 | 0.380 |
Why?
| Systems Biology | 2 | 2021 | 54 | 0.370 |
Why?
| Severity of Illness Index | 10 | 2022 | 2853 | 0.360 |
Why?
| HLA-DR Antigens | 4 | 2015 | 223 | 0.350 |
Why?
| Exosomes | 2 | 2021 | 83 | 0.350 |
Why?
| Aged, 80 and over | 15 | 2020 | 6845 | 0.350 |
Why?
| United States | 13 | 2022 | 12598 | 0.350 |
Why?
| Interferon-gamma | 8 | 2021 | 770 | 0.350 |
Why?
| Glutathione | 3 | 2017 | 335 | 0.350 |
Why?
| Host-Pathogen Interactions | 3 | 2021 | 315 | 0.350 |
Why?
| Immunity, Innate | 3 | 2021 | 742 | 0.340 |
Why?
| Pulmonary Fibrosis | 2 | 2020 | 315 | 0.340 |
Why?
| Smoking | 6 | 2021 | 1596 | 0.340 |
Why?
| Retrospective Studies | 9 | 2022 | 11727 | 0.340 |
Why?
| Logistic Models | 7 | 2020 | 2058 | 0.330 |
Why?
| T-Lymphocytes | 3 | 2014 | 1807 | 0.330 |
Why?
| Administration, Inhalation | 2 | 2020 | 673 | 0.330 |
Why?
| Bronchoalveolar Lavage | 5 | 2021 | 86 | 0.330 |
Why?
| Respiratory Function Tests | 7 | 2019 | 589 | 0.320 |
Why?
| Proteomics | 5 | 2022 | 774 | 0.310 |
Why?
| Pulmonary Diffusing Capacity | 2 | 2018 | 55 | 0.310 |
Why?
| Epitopes, T-Lymphocyte | 3 | 2021 | 168 | 0.300 |
Why?
| Cause of Death | 2 | 2019 | 390 | 0.290 |
Why?
| Mortality | 2 | 2019 | 328 | 0.290 |
Why?
| Bronchoscopy | 5 | 2021 | 243 | 0.290 |
Why?
| Bacteria | 2 | 2021 | 661 | 0.280 |
Why?
| T-Lymphocyte Subsets | 7 | 2013 | 388 | 0.280 |
Why?
| Tomography, X-Ray Computed | 6 | 2020 | 2397 | 0.280 |
Why?
| Membrane Glycoproteins | 1 | 2007 | 495 | 0.280 |
Why?
| Biopsy | 5 | 2020 | 1050 | 0.270 |
Why?
| Occupational Health | 2 | 2020 | 211 | 0.270 |
Why?
| Central Nervous System Diseases | 2 | 2021 | 64 | 0.260 |
Why?
| Radiography, Thoracic | 2 | 2019 | 179 | 0.260 |
Why?
| Neopterin | 1 | 2003 | 11 | 0.250 |
Why?
| Aerosols | 2 | 2020 | 161 | 0.240 |
Why?
| Double-Blind Method | 3 | 2017 | 1682 | 0.240 |
Why?
| Inhalation Exposure | 3 | 2020 | 101 | 0.230 |
Why?
| Duloxetine Hydrochloride | 1 | 2021 | 6 | 0.230 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 76 | 0.230 |
Why?
| Histocompatibility Antigens Class II | 1 | 2003 | 370 | 0.230 |
Why?
| Aspergillus nidulans | 1 | 2021 | 6 | 0.220 |
Why?
| Sputum | 2 | 2014 | 289 | 0.220 |
Why?
| Diagnosis, Differential | 5 | 2021 | 1419 | 0.220 |
Why?
| Animals | 17 | 2021 | 34755 | 0.220 |
Why?
| Dust | 1 | 2022 | 74 | 0.220 |
Why?
| Immunologic Tests | 1 | 2001 | 15 | 0.220 |
Why?
| Nuclear Weapons | 2 | 2011 | 7 | 0.220 |
Why?
| Chemokine CCL3 | 1 | 2021 | 14 | 0.220 |
Why?
| Chemokine CCL4 | 1 | 2021 | 21 | 0.220 |
Why?
| Whole Exome Sequencing | 1 | 2021 | 85 | 0.220 |
Why?
| Silicon Dioxide | 1 | 2022 | 90 | 0.210 |
Why?
| Extracellular Vesicles | 1 | 2022 | 66 | 0.210 |
Why?
| Hydrogen Sulfide | 1 | 2001 | 41 | 0.210 |
Why?
| T-Lymphocytes, Regulatory | 4 | 2021 | 343 | 0.210 |
Why?
| Circulating MicroRNA | 1 | 2021 | 18 | 0.210 |
Why?
| Maximum Allowable Concentration | 1 | 2020 | 11 | 0.210 |
Why?
| Mandibular Nerve | 1 | 2020 | 4 | 0.210 |
Why?
| Societies | 1 | 2020 | 41 | 0.210 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.210 |
Why?
| Tobacco | 1 | 2021 | 149 | 0.210 |
Why?
| Mandibular Fractures | 1 | 2020 | 8 | 0.210 |
Why?
| Salmonella typhimurium | 2 | 2013 | 183 | 0.210 |
Why?
| Arthroplasty, Replacement | 1 | 2021 | 46 | 0.210 |
Why?
| Communicable Diseases | 1 | 2022 | 126 | 0.210 |
Why?
| Cluster Analysis | 1 | 2022 | 469 | 0.200 |
Why?
| Cohort Studies | 3 | 2020 | 5026 | 0.200 |
Why?
| Macrophages | 3 | 2021 | 1325 | 0.200 |
Why?
| Masks | 1 | 2020 | 32 | 0.200 |
Why?
| Mandible | 1 | 2020 | 60 | 0.200 |
Why?
| Unemployment | 1 | 2020 | 41 | 0.200 |
Why?
| Longitudinal Studies | 5 | 2017 | 2676 | 0.200 |
Why?
| Personal Protective Equipment | 1 | 2020 | 42 | 0.200 |
Why?
| Smoke | 1 | 2021 | 133 | 0.200 |
Why?
| Metagenomics | 1 | 2021 | 116 | 0.200 |
Why?
| Interleukin-4 | 1 | 2001 | 215 | 0.200 |
Why?
| B-Lymphocyte Subsets | 1 | 2020 | 83 | 0.200 |
Why?
| African Americans | 3 | 2020 | 952 | 0.190 |
Why?
| Sensitivity and Specificity | 5 | 2013 | 1922 | 0.190 |
Why?
| Pneumoconiosis | 1 | 2019 | 5 | 0.190 |
Why?
| Propensity Score | 1 | 2020 | 253 | 0.190 |
Why?
| Electrocardiography | 2 | 2020 | 656 | 0.190 |
Why?
| Peptidyl-Dipeptidase A | 1 | 1999 | 50 | 0.190 |
Why?
| Income | 1 | 2020 | 173 | 0.190 |
Why?
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 84 | 0.180 |
Why?
| Immunologic Memory | 4 | 2013 | 305 | 0.180 |
Why?
| Kidney Diseases | 2 | 2020 | 402 | 0.180 |
Why?
| Oxygen Inhalation Therapy | 1 | 2020 | 152 | 0.180 |
Why?
| Antioxidants | 2 | 2016 | 557 | 0.180 |
Why?
| Inflammation Mediators | 3 | 2012 | 545 | 0.180 |
Why?
| Residual Volume | 1 | 2018 | 7 | 0.180 |
Why?
| Algorithms | 2 | 2020 | 1519 | 0.180 |
Why?
| Cellular Senescence | 1 | 2019 | 147 | 0.170 |
Why?
| Biological Products | 1 | 2020 | 134 | 0.170 |
Why?
| September 11 Terrorist Attacks | 1 | 2017 | 22 | 0.170 |
Why?
| Chemokines | 2 | 2019 | 239 | 0.170 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 348 | 0.170 |
Why?
| Air Pollutants | 1 | 2001 | 270 | 0.170 |
Why?
| Pilot Projects | 2 | 2020 | 1425 | 0.170 |
Why?
| Cost of Illness | 1 | 2020 | 295 | 0.170 |
Why?
| Arthritis, Juvenile | 1 | 2017 | 37 | 0.170 |
Why?
| Immunologic Factors | 1 | 2020 | 231 | 0.170 |
Why?
| Liver Diseases | 1 | 2020 | 274 | 0.170 |
Why?
| Dental Technicians | 2 | 2014 | 4 | 0.170 |
Why?
| Magnetic Resonance Imaging | 3 | 2020 | 3157 | 0.160 |
Why?
| Gene Expression | 2 | 2021 | 1538 | 0.160 |
Why?
| Firefighters | 1 | 2017 | 35 | 0.160 |
Why?
| Clinical Decision-Making | 1 | 2020 | 281 | 0.160 |
Why?
| Ventricular Function, Right | 1 | 2019 | 233 | 0.160 |
Why?
| Immunoglobulin G | 3 | 2021 | 802 | 0.160 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 99 | 0.160 |
Why?
| Genome, Human | 1 | 2019 | 303 | 0.160 |
Why?
| Betacoronavirus | 1 | 2020 | 262 | 0.160 |
Why?
| Regression Analysis | 2 | 2019 | 1118 | 0.160 |
Why?
| HLA-DQ Antigens | 2 | 2010 | 182 | 0.160 |
Why?
| Global Health | 2 | 2018 | 346 | 0.160 |
Why?
| Pandemics | 2 | 2022 | 956 | 0.160 |
Why?
| Congresses as Topic | 1 | 2018 | 202 | 0.150 |
Why?
| Banking, Personal | 1 | 2016 | 2 | 0.150 |
Why?
| Arrhythmias, Cardiac | 1 | 2019 | 328 | 0.150 |
Why?
| Lung Injury | 1 | 2019 | 222 | 0.150 |
Why?
| Mass Screening | 2 | 2018 | 1067 | 0.150 |
Why?
| Exercise Tolerance | 1 | 2018 | 238 | 0.150 |
Why?
| Deoxyguanosine | 1 | 2016 | 29 | 0.150 |
Why?
| Death Certificates | 1 | 2016 | 24 | 0.150 |
Why?
| Predictive Value of Tests | 5 | 2019 | 1997 | 0.150 |
Why?
| Decision Support Techniques | 1 | 2020 | 384 | 0.150 |
Why?
| Poisson Distribution | 1 | 2016 | 71 | 0.150 |
Why?
| Promoter Regions, Genetic | 3 | 2019 | 1238 | 0.150 |
Why?
| Action Potentials | 1 | 2019 | 452 | 0.150 |
Why?
| Health Care Sector | 1 | 2016 | 32 | 0.150 |
Why?
| Positron-Emission Tomography | 2 | 2020 | 306 | 0.150 |
Why?
| Disease Management | 1 | 2020 | 605 | 0.150 |
Why?
| Ventricular Function, Left | 1 | 2019 | 494 | 0.150 |
Why?
| Gastrointestinal Microbiome | 1 | 2021 | 455 | 0.150 |
Why?
| Commerce | 1 | 2016 | 70 | 0.140 |
Why?
| Adaptive Immunity | 2 | 2019 | 170 | 0.140 |
Why?
| Patch Tests | 3 | 2021 | 42 | 0.140 |
Why?
| Transcription, Genetic | 2 | 2016 | 1463 | 0.140 |
Why?
| Salmonella Infections | 2 | 2013 | 41 | 0.140 |
Why?
| Polymorphism, Single Nucleotide | 4 | 2017 | 1752 | 0.140 |
Why?
| International Classification of Diseases | 1 | 2016 | 129 | 0.140 |
Why?
| alpha 1-Antitrypsin Deficiency | 1 | 2015 | 77 | 0.140 |
Why?
| Metals | 1 | 2016 | 116 | 0.140 |
Why?
| Heart Rate | 1 | 2019 | 839 | 0.140 |
Why?
| Drug Administration Schedule | 2 | 2014 | 809 | 0.140 |
Why?
| Drug Evaluation | 1 | 2014 | 87 | 0.140 |
Why?
| Disease Models, Animal | 3 | 2021 | 3826 | 0.140 |
Why?
| Acetylcysteine | 1 | 2016 | 148 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 336 | 0.140 |
Why?
| Environmental Monitoring | 2 | 2014 | 292 | 0.140 |
Why?
| Young Adult | 8 | 2020 | 11032 | 0.140 |
Why?
| Adolescent | 9 | 2020 | 18712 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2020 | 353 | 0.140 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 357 | 0.130 |
Why?
| Granulomatous Disease, Chronic | 1 | 2014 | 64 | 0.130 |
Why?
| Glucocorticoids | 2 | 2020 | 554 | 0.130 |
Why?
| Metallurgy | 1 | 2014 | 11 | 0.130 |
Why?
| Mice | 8 | 2021 | 15478 | 0.130 |
Why?
| Israel | 1 | 2014 | 39 | 0.130 |
Why?
| Haplotypes | 4 | 2010 | 418 | 0.130 |
Why?
| CD40 Antigens | 1 | 2014 | 86 | 0.130 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 289 | 0.130 |
Why?
| Population Surveillance | 3 | 2009 | 440 | 0.130 |
Why?
| Colorado | 4 | 2020 | 4496 | 0.130 |
Why?
| Heart Diseases | 1 | 2017 | 369 | 0.130 |
Why?
| B-Lymphocytes | 1 | 2019 | 817 | 0.130 |
Why?
| Prednisone | 1 | 2014 | 247 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 778 | 0.130 |
Why?
| Cells, Cultured | 7 | 2013 | 4291 | 0.130 |
Why?
| Genetic Markers | 3 | 2021 | 350 | 0.120 |
Why?
| Occupational Health Services | 1 | 2013 | 38 | 0.120 |
Why?
| Teaching | 1 | 2016 | 246 | 0.120 |
Why?
| Oxidative Stress | 3 | 2016 | 1231 | 0.120 |
Why?
| CTLA-4 Antigen | 1 | 2013 | 79 | 0.120 |
Why?
| Imidazoles | 1 | 2014 | 264 | 0.120 |
Why?
| Pulmonary Gas Exchange | 2 | 2004 | 132 | 0.120 |
Why?
| Nickel | 1 | 2013 | 52 | 0.120 |
Why?
| Apoptosis | 4 | 2005 | 2616 | 0.120 |
Why?
| Myocardial Infarction | 1 | 2021 | 1164 | 0.120 |
Why?
| Phagocytosis | 1 | 2015 | 381 | 0.120 |
Why?
| MAP Kinase Signaling System | 1 | 2014 | 317 | 0.120 |
Why?
| o-Phthalaldehyde | 1 | 2012 | 4 | 0.120 |
Why?
| Dermatitis, Allergic Contact | 1 | 2013 | 63 | 0.120 |
Why?
| NF-kappa B | 2 | 2014 | 723 | 0.120 |
Why?
| Infliximab | 1 | 2012 | 90 | 0.120 |
Why?
| Static Electricity | 1 | 2012 | 117 | 0.120 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2013 | 132 | 0.120 |
Why?
| Ceftriaxone | 1 | 2012 | 20 | 0.120 |
Why?
| Linkage Disequilibrium | 2 | 2010 | 260 | 0.120 |
Why?
| Ciprofloxacin | 1 | 2012 | 25 | 0.110 |
Why?
| Enzyme Activation | 1 | 2014 | 959 | 0.110 |
Why?
| Industry | 2 | 2011 | 86 | 0.110 |
Why?
| Surveys and Questionnaires | 4 | 2021 | 4769 | 0.110 |
Why?
| Monocytes | 1 | 2015 | 513 | 0.110 |
Why?
| Psoriasis | 1 | 2012 | 76 | 0.110 |
Why?
| Radiopharmaceuticals | 1 | 2013 | 200 | 0.110 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 171 | 0.110 |
Why?
| Epidermis | 1 | 2012 | 150 | 0.110 |
Why?
| Amino Acid Substitution | 1 | 2012 | 287 | 0.110 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 1006 | 0.110 |
Why?
| Risk Assessment | 4 | 2020 | 3215 | 0.110 |
Why?
| Gene Frequency | 3 | 2010 | 431 | 0.110 |
Why?
| DNA | 3 | 2016 | 1357 | 0.110 |
Why?
| Hospitalization | 1 | 2020 | 1727 | 0.110 |
Why?
| MicroRNAs | 1 | 2017 | 615 | 0.110 |
Why?
| Receptors, Cell Surface | 3 | 2020 | 398 | 0.110 |
Why?
| Polymerase Chain Reaction | 2 | 2011 | 1048 | 0.100 |
Why?
| Diarrhea | 1 | 2012 | 178 | 0.100 |
Why?
| Forced Expiratory Flow Rates | 1 | 2010 | 16 | 0.100 |
Why?
| Endocytosis | 1 | 1991 | 145 | 0.100 |
Why?
| fas Receptor | 2 | 2008 | 99 | 0.100 |
Why?
| Pyridines | 1 | 2014 | 499 | 0.100 |
Why?
| Genes, MHC Class II | 1 | 2010 | 74 | 0.100 |
Why?
| Interleukins | 1 | 2012 | 238 | 0.100 |
Why?
| Occupations | 2 | 2019 | 41 | 0.100 |
Why?
| Cell Division | 6 | 2013 | 858 | 0.100 |
Why?
| Sulfasalazine | 1 | 2009 | 21 | 0.100 |
Why?
| Prognosis | 3 | 2021 | 3550 | 0.100 |
Why?
| Uveitis | 1 | 2010 | 98 | 0.100 |
Why?
| Diagnostic Errors | 1 | 2011 | 159 | 0.100 |
Why?
| Phosphorylation | 1 | 2014 | 1734 | 0.100 |
Why?
| Sex Factors | 1 | 2016 | 1977 | 0.100 |
Why?
| Research Design | 1 | 2015 | 940 | 0.100 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 28 | 0.090 |
Why?
| Antigens | 2 | 2021 | 341 | 0.090 |
Why?
| Exercise Test | 2 | 2003 | 611 | 0.090 |
Why?
| Up-Regulation | 3 | 2008 | 941 | 0.090 |
Why?
| Homozygote | 2 | 2007 | 195 | 0.090 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 21 | 0.090 |
Why?
| Treatment Outcome | 4 | 2022 | 9218 | 0.090 |
Why?
| Animals, Laboratory | 1 | 2008 | 17 | 0.090 |
Why?
| Biological Evolution | 1 | 2013 | 422 | 0.090 |
Why?
| Genetic Variation | 2 | 2019 | 825 | 0.090 |
Why?
| HLA-DRB1 Chains | 2 | 2010 | 93 | 0.090 |
Why?
| HLA-D Antigens | 1 | 2008 | 39 | 0.090 |
Why?
| Butyrophilins | 1 | 2007 | 6 | 0.090 |
Why?
| Multivariate Analysis | 3 | 2020 | 1607 | 0.090 |
Why?
| Eye Diseases | 2 | 2020 | 80 | 0.080 |
Why?
| CD57 Antigens | 1 | 2007 | 14 | 0.080 |
Why?
| Antigen Presentation | 2 | 2005 | 212 | 0.080 |
Why?
| Prevalence | 2 | 2011 | 2403 | 0.080 |
Why?
| Antigens, CD | 2 | 2008 | 491 | 0.080 |
Why?
| Time Factors | 3 | 2019 | 7041 | 0.080 |
Why?
| Fatal Outcome | 1 | 2008 | 314 | 0.080 |
Why?
| Proto-Oncogene Proteins | 1 | 1991 | 715 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 213 | 0.080 |
Why?
| Genome-Wide Association Study | 3 | 2019 | 948 | 0.080 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2006 | 18 | 0.080 |
Why?
| Total Lung Capacity | 1 | 2006 | 44 | 0.080 |
Why?
| Protein Binding | 1 | 2012 | 2056 | 0.080 |
Why?
| Transforming Growth Factor beta1 | 1 | 2007 | 167 | 0.080 |
Why?
| Reactive Oxygen Species | 2 | 2008 | 559 | 0.080 |
Why?
| B7-2 Antigen | 2 | 2017 | 29 | 0.080 |
Why?
| Transcriptome | 2 | 2021 | 685 | 0.070 |
Why?
| Chemical Industry | 1 | 2005 | 12 | 0.070 |
Why?
| Toll-Like Receptor 4 | 1 | 2008 | 383 | 0.070 |
Why?
| Cell Line | 5 | 2013 | 2930 | 0.070 |
Why?
| Nuclear Warfare | 1 | 2004 | 7 | 0.070 |
Why?
| Biomarkers, Tumor | 1 | 1991 | 1060 | 0.070 |
Why?
| Mice, Transgenic | 2 | 2021 | 2108 | 0.070 |
Why?
| Metabolomics | 2 | 2021 | 536 | 0.070 |
Why?
| Ferritins | 1 | 2004 | 55 | 0.070 |
Why?
| Protein Structure, Secondary | 1 | 2005 | 388 | 0.070 |
Why?
| Reproducibility of Results | 3 | 2021 | 2940 | 0.070 |
Why?
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.070 |
Why?
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.070 |
Why?
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2017 | 4959 | 0.060 |
Why?
| HLA-DQ beta-Chains | 1 | 2003 | 66 | 0.060 |
Why?
| Decision Making | 1 | 2010 | 799 | 0.060 |
Why?
| Societies, Medical | 2 | 2020 | 764 | 0.060 |
Why?
| Thorax | 1 | 2022 | 49 | 0.060 |
Why?
| Aluminum | 1 | 2002 | 38 | 0.060 |
Why?
| Cobalt | 1 | 2002 | 50 | 0.060 |
Why?
| Granuloma, Respiratory Tract | 1 | 2002 | 11 | 0.060 |
Why?
| Inflammation | 4 | 2019 | 2457 | 0.060 |
Why?
| Immunity, Active | 1 | 2002 | 10 | 0.060 |
Why?
| DNA Probes, HLA | 1 | 2001 | 1 | 0.060 |
Why?
| Cells | 1 | 2021 | 22 | 0.060 |
Why?
| Epitopes | 1 | 2003 | 424 | 0.060 |
Why?
| Th17 Cells | 1 | 2021 | 57 | 0.060 |
Why?
| Antigens, Fungal | 1 | 2021 | 32 | 0.060 |
Why?
| Eosinophil Cationic Protein | 1 | 2021 | 8 | 0.060 |
Why?
| Oxygen Consumption | 1 | 2004 | 660 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2021 | 64 | 0.050 |
Why?
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 36 | 0.050 |
Why?
| Mining | 1 | 2001 | 16 | 0.050 |
Why?
| Bronchiolitis | 1 | 2002 | 79 | 0.050 |
Why?
| Administration, Oral | 2 | 2016 | 798 | 0.050 |
Why?
| Minimal Clinically Important Difference | 1 | 2021 | 6 | 0.050 |
Why?
| HLA-DR3 Antigen | 1 | 2021 | 78 | 0.050 |
Why?
| CD55 Antigens | 1 | 2021 | 24 | 0.050 |
Why?
| CD28 Antigens | 2 | 2013 | 42 | 0.050 |
Why?
| Chemokine CXCL9 | 1 | 2021 | 20 | 0.050 |
Why?
| Hybridomas | 1 | 2021 | 239 | 0.050 |
Why?
| Click Chemistry | 1 | 2021 | 50 | 0.050 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 223 | 0.050 |
Why?
| Trigeminal Nerve Injuries | 1 | 2020 | 2 | 0.050 |
Why?
| Bone Cements | 1 | 2021 | 37 | 0.050 |
Why?
| Biomedical Engineering | 1 | 2020 | 22 | 0.050 |
Why?
| CD11c Antigen | 1 | 2020 | 38 | 0.050 |
Why?
| Mice, Inbred C57BL | 3 | 2019 | 5151 | 0.050 |
Why?
| Fungal Proteins | 1 | 2021 | 142 | 0.050 |
Why?
| Lymphadenopathy | 1 | 2020 | 4 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 887 | 0.050 |
Why?
| Textiles | 1 | 2020 | 14 | 0.050 |
Why?
| Serologic Tests | 1 | 2020 | 58 | 0.050 |
Why?
| Mediastinum | 1 | 2020 | 20 | 0.050 |
Why?
| Chi-Square Distribution | 3 | 2011 | 577 | 0.050 |
Why?
| Fatigue Syndrome, Chronic | 1 | 2020 | 18 | 0.050 |
Why?
| Receptors, Fc | 1 | 2020 | 42 | 0.050 |
Why?
| Hypercalcemia | 1 | 2020 | 23 | 0.050 |
Why?
| Radiography | 1 | 2003 | 851 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2020 | 83 | 0.050 |
Why?
| Self-Help Devices | 1 | 2020 | 22 | 0.050 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 61 | 0.050 |
Why?
| Medical History Taking | 1 | 2020 | 129 | 0.050 |
Why?
| Electrocardiography, Ambulatory | 1 | 2020 | 66 | 0.050 |
Why?
| Prospective Studies | 2 | 2022 | 6324 | 0.050 |
Why?
| Communicable Disease Control | 1 | 2020 | 69 | 0.050 |
Why?
| Fractals | 1 | 2019 | 8 | 0.050 |
Why?
| Aspartate Aminotransferases | 1 | 2020 | 100 | 0.050 |
Why?
| Radionuclide Imaging | 1 | 2019 | 155 | 0.050 |
Why?
| Breast Neoplasms | 1 | 1991 | 1934 | 0.050 |
Why?
| Cryosurgery | 1 | 2020 | 58 | 0.050 |
Why?
| Mobility Limitation | 1 | 2020 | 67 | 0.050 |
Why?
| Tertiary Lymphoid Structures | 1 | 2019 | 6 | 0.050 |
Why?
| Antidepressive Agents | 1 | 2021 | 208 | 0.050 |
Why?
| Chemokine CXCL13 | 1 | 2019 | 9 | 0.050 |
Why?
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 28 | 0.050 |
Why?
| Delphi Technique | 1 | 2020 | 139 | 0.050 |
Why?
| Prostheses and Implants | 1 | 2021 | 159 | 0.050 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 158 | 0.050 |
Why?
| Receptors, Complement 3d | 1 | 2020 | 154 | 0.050 |
Why?
| Alanine Transaminase | 1 | 2020 | 154 | 0.050 |
Why?
| Receptors, Immunologic | 1 | 2020 | 207 | 0.050 |
Why?
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 40 | 0.050 |
Why?
| GTPase-Activating Proteins | 1 | 2019 | 67 | 0.050 |
Why?
| Models, Animal | 1 | 2021 | 391 | 0.050 |
Why?
| Pulmonary Medicine | 1 | 2020 | 84 | 0.050 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2013 | 178 | 0.050 |
Why?
| Amino Acid Sequence | 3 | 2013 | 2161 | 0.050 |
Why?
| Systole | 1 | 2019 | 196 | 0.050 |
Why?
| Exoribonucleases | 1 | 2019 | 47 | 0.050 |
Why?
| Spirometry | 1 | 2019 | 291 | 0.050 |
Why?
| Endosonography | 1 | 2020 | 139 | 0.050 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2019 | 125 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 405 | 0.040 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2019 | 105 | 0.040 |
Why?
| Interleukin-2 | 2 | 2013 | 403 | 0.040 |
Why?
| Reoperation | 1 | 2021 | 546 | 0.040 |
Why?
| Mass Spectrometry | 1 | 2022 | 704 | 0.040 |
Why?
| Electric Countershock | 1 | 2019 | 130 | 0.040 |
Why?
| Confidence Intervals | 1 | 1999 | 339 | 0.040 |
Why?
| Telomere-Binding Proteins | 1 | 2019 | 90 | 0.040 |
Why?
| Creatinine | 1 | 2020 | 465 | 0.040 |
Why?
| DNA Helicases | 1 | 2019 | 125 | 0.040 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 2 | 0.040 |
Why?
| Lipopolysaccharides | 2 | 2016 | 957 | 0.040 |
Why?
| Janus Kinase 1 | 1 | 2017 | 25 | 0.040 |
Why?
| Cross-Sectional Studies | 2 | 2011 | 4445 | 0.040 |
Why?
| Consensus | 1 | 2020 | 461 | 0.040 |
Why?
| New York City | 1 | 2017 | 72 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 1005 | 0.040 |
Why?
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 47 | 0.040 |
Why?
| Mucin-5B | 1 | 2019 | 152 | 0.040 |
Why?
| High Mobility Group Proteins | 1 | 2017 | 52 | 0.040 |
Why?
| Caenorhabditis elegans | 1 | 2021 | 349 | 0.040 |
Why?
| RNA Splicing Factors | 1 | 2017 | 51 | 0.040 |
Why?
| Epigenomics | 1 | 2017 | 90 | 0.040 |
Why?
| Telomerase | 1 | 2019 | 223 | 0.040 |
Why?
| Forecasting | 1 | 2019 | 389 | 0.040 |
Why?
| Epigenesis, Genetic | 1 | 2021 | 494 | 0.040 |
Why?
| Lymph Nodes | 1 | 2020 | 476 | 0.040 |
Why?
| Death, Sudden, Cardiac | 1 | 2019 | 225 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 3 | 2004 | 2187 | 0.040 |
Why?
| Echocardiography | 1 | 2020 | 623 | 0.040 |
Why?
| Chronic Pain | 1 | 2020 | 201 | 0.040 |
Why?
| Sleep Apnea, Obstructive | 1 | 2020 | 224 | 0.040 |
Why?
| Vitamin D | 1 | 2020 | 345 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 419 | 0.040 |
Why?
| Poverty | 1 | 2020 | 461 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 735 | 0.040 |
Why?
| Stroke Volume | 1 | 2019 | 531 | 0.040 |
Why?
| Base Sequence | 2 | 2014 | 2280 | 0.040 |
Why?
| Sleep Wake Disorders | 1 | 2020 | 310 | 0.040 |
Why?
| Hospitals | 1 | 2020 | 503 | 0.040 |
Why?
| Software | 1 | 2019 | 517 | 0.040 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1199 | 0.040 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2017 | 222 | 0.040 |
Why?
| Mitochondrial Proteins | 1 | 2017 | 231 | 0.040 |
Why?
| Quantitative Trait Loci | 1 | 2017 | 306 | 0.040 |
Why?
| Brain Diseases | 1 | 1997 | 156 | 0.040 |
Why?
| Linear Models | 1 | 2018 | 889 | 0.040 |
Why?
| Skin Diseases | 1 | 1997 | 153 | 0.030 |
Why?
| Health Personnel | 1 | 2020 | 520 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 406 | 0.030 |
Why?
| Comorbidity | 1 | 2020 | 1654 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 387 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 2019 | 405 | 0.030 |
Why?
| Repressor Proteins | 1 | 2017 | 402 | 0.030 |
Why?
| Protective Devices | 1 | 2014 | 36 | 0.030 |
Why?
| Heme Oxygenase-1 | 1 | 2014 | 50 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2014 | 3014 | 0.030 |
Why?
| United States Occupational Safety and Health Administration | 1 | 2013 | 6 | 0.030 |
Why?
| Membrane Proteins | 1 | 2020 | 1092 | 0.030 |
Why?
| Calcium | 1 | 2020 | 1208 | 0.030 |
Why?
| Hematologic Tests | 1 | 2013 | 25 | 0.030 |
Why?
| Cardiac Imaging Techniques | 1 | 2013 | 26 | 0.030 |
Why?
| B7-1 Antigen | 1 | 2013 | 63 | 0.030 |
Why?
| RNA | 1 | 2019 | 779 | 0.030 |
Why?
| Lymphokines | 1 | 2013 | 145 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 82 | 0.030 |
Why?
| Flow Cytometry | 2 | 2000 | 1167 | 0.030 |
Why?
| Etanercept | 1 | 2012 | 54 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2016 | 981 | 0.030 |
Why?
| Infusions, Parenteral | 1 | 2012 | 41 | 0.030 |
Why?
| Mice, Knockout | 1 | 2019 | 2835 | 0.030 |
Why?
| Colony Count, Microbial | 1 | 2012 | 85 | 0.030 |
Why?
| Virulence | 1 | 2013 | 239 | 0.030 |
Why?
| Phagocytes | 2 | 2004 | 97 | 0.030 |
Why?
| Microscopy, Immunoelectron | 1 | 1991 | 47 | 0.030 |
Why?
| Hyperplasia | 1 | 2012 | 168 | 0.030 |
Why?
| Immunotoxins | 1 | 1991 | 29 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2013 | 205 | 0.030 |
Why?
| Virulence Factors | 1 | 2013 | 139 | 0.030 |
Why?
| Body Mass Index | 1 | 2019 | 2060 | 0.030 |
Why?
| Ontario | 1 | 2011 | 62 | 0.030 |
Why?
| Depression | 1 | 2020 | 1192 | 0.030 |
Why?
| Hypertension | 1 | 2020 | 1194 | 0.030 |
Why?
| Genomics | 1 | 2015 | 518 | 0.030 |
Why?
| Self Report | 1 | 2015 | 717 | 0.030 |
Why?
| Needs Assessment | 1 | 2013 | 343 | 0.030 |
Why?
| Program Development | 1 | 2013 | 370 | 0.030 |
Why?
| Keratinocytes | 1 | 2012 | 244 | 0.030 |
Why?
| Gold | 1 | 1991 | 101 | 0.030 |
Why?
| Educational Measurement | 1 | 2013 | 298 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 429 | 0.030 |
Why?
| Netherlands | 1 | 2010 | 73 | 0.030 |
Why?
| Regeneration | 1 | 2012 | 175 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 148 | 0.030 |
Why?
| Japan | 1 | 2010 | 100 | 0.030 |
Why?
| Plasmids | 1 | 1991 | 387 | 0.030 |
Why?
| Chromosome Mapping | 1 | 1991 | 509 | 0.030 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 52 | 0.020 |
Why?
| Intestines | 1 | 2013 | 310 | 0.020 |
Why?
| United Kingdom | 1 | 2010 | 231 | 0.020 |
Why?
| CD3 Complex | 1 | 2010 | 95 | 0.020 |
Why?
| Feces | 1 | 2012 | 368 | 0.020 |
Why?
| Binding Sites | 1 | 2013 | 1292 | 0.020 |
Why?
| Risk | 2 | 2004 | 945 | 0.020 |
Why?
| Down-Regulation | 1 | 2012 | 666 | 0.020 |
Why?
| Antigen-Presenting Cells | 1 | 2009 | 164 | 0.020 |
Why?
| Hypertension, Pulmonary | 1 | 2020 | 1681 | 0.020 |
Why?
| Forkhead Transcription Factors | 1 | 2010 | 180 | 0.020 |
Why?
| 4-1BB Ligand | 1 | 2008 | 7 | 0.020 |
Why?
| Transfection | 1 | 1991 | 964 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 1991 | 328 | 0.020 |
Why?
| Demography | 1 | 2009 | 285 | 0.020 |
Why?
| Blood Proteins | 1 | 2011 | 260 | 0.020 |
Why?
| Program Evaluation | 1 | 2013 | 877 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2010 | 345 | 0.020 |
Why?
| Immunophenotyping | 1 | 2009 | 297 | 0.020 |
Why?
| Peptides | 1 | 2013 | 865 | 0.020 |
Why?
| Codon | 1 | 2007 | 90 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 1500 | 0.020 |
Why?
| Fibrosis | 1 | 2009 | 414 | 0.020 |
Why?
| RNA, Messenger | 2 | 2006 | 2835 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2008 | 231 | 0.020 |
Why?
| Fibroblasts | 1 | 1991 | 869 | 0.020 |
Why?
| Obesity | 1 | 2020 | 2649 | 0.020 |
Why?
| Transcription Factor AP-1 | 1 | 2006 | 85 | 0.020 |
Why?
| Gene Dosage | 1 | 2006 | 134 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 1139 | 0.020 |
Why?
| Catalytic Domain | 1 | 2006 | 199 | 0.020 |
Why?
| RNA Precursors | 1 | 2006 | 142 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 57 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 288 | 0.020 |
Why?
| Cell Separation | 1 | 2006 | 309 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2005 | 145 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2005 | 89 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2005 | 388 | 0.020 |
Why?
| Radioisotopes | 1 | 2004 | 40 | 0.020 |
Why?
| Metalloporphyrins | 1 | 2005 | 106 | 0.020 |
Why?
| Infant | 1 | 2017 | 8124 | 0.020 |
Why?
| Models, Theoretical | 1 | 2008 | 617 | 0.020 |
Why?
| Caspases | 1 | 2005 | 285 | 0.020 |
Why?
| Species Specificity | 1 | 2005 | 619 | 0.020 |
Why?
| In Vitro Techniques | 1 | 2005 | 1231 | 0.020 |
Why?
| Child, Preschool | 1 | 2017 | 9680 | 0.020 |
Why?
| Kinetics | 1 | 2006 | 1759 | 0.010 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 1376 | 0.010 |
Why?
| In Situ Nick-End Labeling | 1 | 2002 | 138 | 0.010 |
Why?
| Mutation | 1 | 2013 | 3403 | 0.010 |
Why?
| Rats | 1 | 1991 | 6191 | 0.010 |
Why?
| Incidence | 1 | 2008 | 2456 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2002 | 195 | 0.010 |
Why?
| Nuclear Proteins | 1 | 2006 | 634 | 0.010 |
Why?
| Utah | 1 | 2001 | 64 | 0.010 |
Why?
| Oximetry | 1 | 2001 | 88 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 90 | 0.010 |
Why?
| Tetanus Toxoid | 1 | 2000 | 43 | 0.010 |
Why?
| Bromodeoxyuridine | 1 | 2000 | 81 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2000 | 72 | 0.010 |
Why?
| Volatilization | 1 | 2000 | 60 | 0.010 |
Why?
| HLA-DP alpha-Chains | 1 | 1999 | 3 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2004 | 606 | 0.010 |
Why?
| Genetic Carrier Screening | 1 | 1999 | 28 | 0.010 |
Why?
| Scattering, Radiation | 1 | 2000 | 117 | 0.010 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 132 | 0.010 |
Why?
| Dimerization | 1 | 1999 | 202 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 995 | 0.010 |
Why?
| Child | 1 | 2017 | 17937 | 0.010 |
Why?
| Fluorescent Dyes | 1 | 2000 | 306 | 0.010 |
Why?
| Equipment Design | 1 | 2000 | 533 | 0.010 |
Why?
| Transcription Factors | 1 | 2006 | 1623 | 0.010 |
Why?
| Cell Movement | 1 | 2002 | 933 | 0.010 |
Why?
| Skin | 1 | 2002 | 680 | 0.010 |
Why?
| Light | 1 | 2000 | 365 | 0.010 |
Why?
| Oxygen | 1 | 2001 | 882 | 0.010 |
Why?
|
|
Maier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|